Piper Sandler Maintains Overweight on Abbott Laboratories, Raises Price Target to $133

Benzinga · 10/17 12:32
Piper Sandler analyst Adam Maeder maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $131 to $133.